The pharmaceutical company Pfizer announced on Tuesday that Paxlovid, its antiviral pill against covid-19 , has shown an efficacy of 89% against hospitalization and death in phase II / III clinical trials. This efficacy has been seen in high-risk adults who started treatment within three days of symptom onset.
This has been announced by the company in a statement in which it also states that the efficacy was 88% compared to hospital admissions and death when the treatment (nirmatrelvir and ritonavir) was administered within five days of the onset of symptoms.
According to the data presented by Pfizer, the efficacy observed in the cohort of adults at normal risk for covid has been 70% compared to hospitalization and in them there were no deaths during the trials.
In addition, their data suggest that this drug would maintain “robust” efficacy against variants of concern, including the new omicron variant . However, Pfizer notes that “more in vitro antiviral studies are being conducted with this variant.”
Phase 2/3 of the trials have been carried out with 2,246 adults . These final results, which surpass previously seen inmates, who demonstrated 85% efficacy when administered within five days of symptom onset, have already been submitted to the US Food and Drug Administration ( FDA). for evaluation and authorization for the emergency use of this drug.
